Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Dalutrafusp Alfa · AGEN1423

Bispecific antibody · Immune activation, directed at CD73 (NT5E) and TGF-beta (TGFB1)

Phase 2 Most advanced trial
1 Registered trials

What is Dalutrafusp Alfa?

Dalutrafusp alfa is a bifunctional antibody fused to the extracellular domain of TGF-beta receptor type II. It binds CD73 on tumor cells and TGF-beta in the tumor microenvironment, blocking adenosine-mediated immunosuppression and TGF-beta signaling. This enhances cytotoxic T-lymphocyte activity and anti-tumor immunity. It is studied in metastatic colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AGEN1423
Drug type
Bispecific antibody
Targets
CD73 (NT5E), TGF-beta (TGFB1)
Mechanism
Immune activation, directed at CD73 (NT5E) and TGF-beta (TGFB1)
Pathways
immune_activation, CTL-mediated immunity, adenosine signaling suppression
Therapy area
Oncology
In trials of
AGEN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
KNL22F1WCK

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06300463 Phase 2 Colorectal Cancer Metastatic Recruiting AGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CancerColorectal Cancer MetastaticLiver Metastases

Other drugs acting on NT5E / TGFB1

Ficerafusp Alfa Phase 2/3 Linavonkibart Phase 1 ORIC-533 Phase 1 Quemliclustat Phase 2 STP707 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.